Literature DB >> 22520978

Targeting the insulin growth factor receptor 1.

Fernanda I Arnaldez1, Lee J Helman.   

Abstract

The IGF axis is a tightly controlled endocrine system that regulates cell growth and development, known to have an important function in cancer biology. IGF1 and IGF2 can promote cancer growth in a GH-independent manner both through paracrine and autocrine secretion and can also confer resistance to chemotherapy and radiation. Many alterations of this system have been found in neoplasias, including increased expression of ligands and receptors, loss of heterozygosity of the IGF2 locus and increased IGF1R gene copy number. The IGF1 network is an attractive candidate for targeted therapy, including receptor blockade with monoclonal antibodies and small molecule inhibitors of receptor downstream signaling. This article reviews the role of the IGF axis in the initiation and progression of cancer, and describes the recent advances in IGF inhibition as a therapeutic tool. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22520978      PMCID: PMC3334849          DOI: 10.1016/j.hoc.2012.01.004

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  123 in total

1.  Inhibition of the insulin-like growth factor 1 receptor pathway enhances the antitumor effect of cisplatin in human malignant mesothelioma cell lines.

Authors:  Kiyonori Kai; Susan D'Costa; Robert C Sills; Yongbaek Kim
Journal:  Cancer Lett       Date:  2009-06-08       Impact factor: 8.679

2.  Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival.

Authors:  Jennifer H Law; Golareh Habibi; Kaiji Hu; Hamid Masoudi; Michelle Y C Wang; Anna L Stratford; Eugene Park; Julia M W Gee; Pauline Finlay; Helen E Jones; Robert I Nicholson; Joan Carboni; Marco Gottardis; Michael Pollak; Sandra E Dunn
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

3.  Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling.

Authors:  Thomas J Giordano; Rork Kuick; Tobias Else; Paul G Gauger; Michelle Vinco; Juliane Bauersfeld; Donita Sanders; Dafydd G Thomas; Gerard Doherty; Gary Hammer
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

Review 4.  The role of IGF-1 receptor and insulin receptor signaling for the pathogenesis of Alzheimer's disease: from model organisms to human disease.

Authors:  S Freude; K Schilbach; M Schubert
Journal:  Curr Alzheimer Res       Date:  2009-06       Impact factor: 3.498

5.  Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer.

Authors:  Daniel D Karp; Luis G Paz-Ares; Silvia Novello; Paul Haluska; Linda Garland; Felipe Cardenal; L Johnetta Blakely; Peter D Eisenberg; Corey J Langer; George Blumenschein; Faye M Johnson; Stephanie Green; Antonio Gualberto
Journal:  J Clin Oncol       Date:  2009-04-20       Impact factor: 44.544

Review 6.  Targeting IGF-1R in the treatment of sarcomas: past, present and future.

Authors:  Su Young Kim; Xiaolin Wan; Lee J Helman
Journal:  Bull Cancer       Date:  2009 Jul-Aug       Impact factor: 1.276

7.  Recombinant human insulin-like growth factor-binding protein 3 inhibits tumor growth and targets the Akt pathway in lung and colon cancer models.

Authors:  Nezha Alami; Viviane Page; Qingnan Yu; Lori Jerome; Jesse Paterson; Laura Shiry; Brian Leyland-Jones
Journal:  Growth Horm IGF Res       Date:  2008-05-23       Impact factor: 2.372

8.  Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition.

Authors:  Nikolaos A Dallas; Ling Xia; Fan Fan; Michael J Gray; Puja Gaur; George van Buren; Shaija Samuel; Michael P Kim; Sherry J Lim; Lee M Ellis
Journal:  Cancer Res       Date:  2009-02-24       Impact factor: 12.701

9.  Mannose-6-phosphate/insulin-like growth factor-II receptor in human melanoma cells: effect of ligands and antibodies on the receptor expression.

Authors:  Friedemann Laube
Journal:  Anticancer Res       Date:  2009-04       Impact factor: 2.480

Review 10.  Insulin and insulin-like growth factor signalling in neoplasia.

Authors:  Michael Pollak
Journal:  Nat Rev Cancer       Date:  2008-12       Impact factor: 60.716

View more
  40 in total

Review 1.  Risk of Neoplasia in Pediatric Patients Receiving Growth Hormone Therapy--A Report From the Pediatric Endocrine Society Drug and Therapeutics Committee.

Authors:  Sripriya Raman; Adda Grimberg; Steven G Waguespack; Bradley S Miller; Charles A Sklar; Lillian R Meacham; Briana C Patterson
Journal:  J Clin Endocrinol Metab       Date:  2015-04-03       Impact factor: 5.958

Review 2.  Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy.

Authors:  Terry J Smith; Joseph A M J L Janssen
Journal:  Endocr Rev       Date:  2019-02-01       Impact factor: 19.871

3.  Phase I dose-escalation study evaluating safety, tolerability and pharmacokinetics of MEDI-573, a dual IGF-I/II neutralizing antibody, in Japanese patients with advanced solid tumours.

Authors:  Haruo Iguchi; Tomohiro Nishina; Naoyuki Nogami; Toshiyuki Kozuki; Yumiko Yamagiwa; Katsuro Yagawa
Journal:  Invest New Drugs       Date:  2014-10-25       Impact factor: 3.850

Review 4.  On the Run for Hippocampal Plasticity.

Authors:  C'iana Cooper; Hyo Youl Moon; Henriette van Praag
Journal:  Cold Spring Harb Perspect Med       Date:  2018-04-02       Impact factor: 6.915

Review 5.  Generating new neurons to circumvent your fears: the role of IGF signaling.

Authors:  R C Agis-Balboa; A Fischer
Journal:  Cell Mol Life Sci       Date:  2013-03-30       Impact factor: 9.261

Review 6.  Adrenocortical carcinoma.

Authors:  Tobias Else; Alex C Kim; Aaron Sabolch; Victoria M Raymond; Asha Kandathil; Elaine M Caoili; Shruti Jolly; Barbra S Miller; Thomas J Giordano; Gary D Hammer
Journal:  Endocr Rev       Date:  2013-12-20       Impact factor: 19.871

Review 7.  The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development.

Authors:  T F Sumter; L Xian; T Huso; M Koo; Y-T Chang; T N Almasri; L Chia; C Inglis; D Reid; L M S Resar
Journal:  Curr Mol Med       Date:  2016       Impact factor: 2.222

8.  The Potent Humanin Analogue (HNG) Protects Germ Cells and Leucocytes While Enhancing Chemotherapy-Induced Suppression of Cancer Metastases in Male Mice.

Authors:  YanHe Lue; Ronald Swerdloff; Junxiang Wan; Jialin Xiao; Samuel French; Vince Atienza; Victor Canela; Kevin W Bruhn; Brian Stone; Yue Jia; Pinchas Cohen; Christina Wang
Journal:  Endocrinology       Date:  2015-09-18       Impact factor: 4.736

9.  Insulin-Like Growth Factor-1 Receptor Expression and Disease Recurrence and Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma.

Authors:  Chunxia Du; Annacarolina da Silva; Vicente Morales-Oyarvide; Brian M Wolpin; Jonathan A Nowak; Andressa Dias Costa; Margaret M Kozak; Richard F Dunne; Douglas A Rubinson; Kimberly Perez; Yohei Masugi; Tsuyoshi Hamada; Lauren K Brais; Chen Yuan; Ana Babic; Matthew D Ducar; Aaron R Thorner; Andrew Aguirre; Matthew H Kulke; Kimmie Ng; Thomas E Clancy; Jennifer J Findeis-Hosey; Daniel T Chang; Jason L Hornick; Charles S Fuchs; Shuji Ogino; Albert C Koong; Aram F Hezel
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-05-28       Impact factor: 4.254

Review 10.  MicroRNA and signal transduction pathways in tumor radiation response.

Authors:  Luqing Zhao; Xiongbin Lu; Ya Cao
Journal:  Cell Signal       Date:  2013-04-17       Impact factor: 4.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.